



---

# Status of Clinical Development

November 2, 2005

Toshiaki Nishihata, Ph.D.  
Senior Corporate Officer  
Head of Research and Development Division



## Major Product Pipelines

Generic name (Development code)	Indication	Category/Mechanism	Region	P 2a	P 2b	P3	NDA planned
Tafluprost (DE-085)	Glaucoma and ocular hypertension	Prostanoid FP-receptor agonist. Promotes uveoscleral outflow	Japan				3Q 06FY
			US/ Europe				
Olmesartan (DE-092)	Glaucoma and ocular hypertension	Angiotensin II AT1 receptor antagonist. Promotes uvescleral outflow	Japan				1Q 08FY (P3: 2Q 06FY)
			US/ Europe	(P2)			
Diquafosol tetrasodium (DE-089)	Corneal and conjunctival epithelial disorder associated with dry eye, etc.	P2Y <sub>2</sub> receptor agonist. Stimulates tear secretion	Japan				3Q 08FY (P3: 2Q 06FY)



## Pre-clinical development

---

Drug candidates

Clinical development to start in 2006-2007

- Cornea: DE-101 (CS-011)
- Glaucoma
- Retina
- Rheumatoid arthritis

One project of each  
area is under  
preclinical development



## FY2005 topics (as of November 2)

---

### 1. Ciclosporin

- Approved in October 2005
- Indication: Vernal keratoconjunctivitis (in patients whose symptoms cannot be adequately controlled by anti-allergy drugs)
- Brand name: PAPILOCK Mini ophthalmic solution 0.1%
- Orphan drug

### 2. DE-101(CS-011): Signed an agreement with Sankyo

- Indication: Corneal and conjunctival epithelial disorder associated with dry eye.
- In preparation for clinical study

### 3. DE-096

- Diabetic Macular Edema: In preparation for Phase IIa → Phase II



[Appendix]



# Product Pipeline: Glaucoma and Retina

## Glaucoma

Generic name (Development code)	Indication	Category/Mechanism	Original/Licensor	Stage
Tafluprost (DE-085)	Glaucoma and ocular hypertension	Prostanoid FP-receptor agonist. Promotes uveoscleral outflow	Original (co-development with Asahi Glass)	Japan: P3 US/Europe: P3
Olmesartan (DE-092)	Glaucoma and ocular hypertension	Angiotensin II AT1 receptor antagonist. Promotes uvescleral outflow	In-licensed (Sankyo)	Japan: P2b US/Europe: P2
Lomerizine hydrochloride (DE-090)	Glaucoma	Calcium channel blocker. Improves ocular blood-flow circulation	In-licensed (Nippon Organon)	Japan: P2a

## Retina

Generic name (Development code)	Indication	Category/Mechanism	Original/Licensor	Stage
Undetermined (DE-096)	Diabetes MacularEdema	An oral TNF-alpha inhibitor Inhibits production of TNF-alpha	Original	<u>P2a</u>

Underlined part shows changes from announcement of May 10, 2005



## Product Pipeline: Cornea

Generic name (Development code/ brand name)	Indication	Category/Mechanism	Original/ Licensor	Stage
Diquafosol tetrasodium (DE-089)	Corneal & conjunctival epithelial disorder associated with dry eye, etc.	P2Y <sub>2</sub> receptor agonist. Stimulates tear secretion	In-licensed (Inspire)	Japan: P2b
Gefarnate (DE-099)	Corneal & conjunctival epithelial disorder associated with dry eye, etc.	Muco-membranous protective agent. Stimulates mucin secretion	Original	Japan: P1
*Rivoglitazone (DE-101)	Corneal & conjunctival epithelial disorder associated with dry eye, etc.	Directory acting on the corneal and conjunctival epithelial cell	In-licensed (Sankyo)	<u>USA: In preparation for clinical study</u>

Underlined part shows changes from announcement of May 10, 2005. \*Rivoglitazone: Generic name in the USA



## Product Pipeline: Anti-inflammatory and Anti-infective

Generic name (Development code/ brand name)	Indication	Category/Mechanism	Original/ Licensor	Stage
Levofloxacin 1.5% (IQUIX)	Bacterial corneal ulcer	DNA gyrase inhibitor. Anti-intefcive action	In-licensed (Daiichi)	<u>US: Suspended launch plan</u>
Ciclosporin (DE-076)	Vernal kerato- conjunctivitis	Calicyneurin inhibitor. Immunosuppressant	In-licensed (Novartis)	<u>Japan: Approved</u>
Levofloxacin + Prednisolone (DE-094)	Infectious keratitis	Fluoroquinolone + steroid. Anti-infective + anti- inflammatory action	In-licensed (Daiichi)	US: P2

Underlined part shows changes from announcement of May 10, 2005.





## Product Pipeline: Bones and Joints

Generic name (Development code/brand name)	Indication	Category/Mechanism	Original/ Licensor	Stage
Undetermined (DE-096)	Rheumatoid Arthritis (RA)	TNF-alpha inhibitor. Inhibits production of TNF-alpha	Original	Japan: P2a
Bucillamine (Rimatil)	Osteoarthritis	DMAOD Protects cartilage and modifies edema	Original	Japan: preparing for clinical study

### ● License out

Generic name (Development code/ brand name)	Indication	Category/Mechanism	Licensee	Stage
Undetermined (DE-098)	Rheumatoid Arthritis (RA)	Anti-APO-1 antibody. Induces apoptosis in synovial cells	Argenes	Japan: preparing for clinical study